Navigation Links
Inflammatory on and off switch identified for allergic asthma and COPD
Date:8/1/2013

Bethesda, MDJapanese researchers have made a new step toward understanding whyand how to stoprunaway inflammation for both chronic obstructive pulmonary disorder (COPD) and allergic asthma. In a new report appearing in the August 2013 issue of The FASEB Journal scientists show that two receptors of an inflammatory molecule, called "leukotriene B4," play opposing roles in turning inflammation on and off for allergic asthma and COPD. The first receptor, called "BLT1," promotes inflammation, while the second receptor, called "BLT2," has a potential to weaken inflammation during an allergic reaction. This discovery also is important because until now, BLT2 was believed to increase inflammatory reaction.

"Leukotriene B4 levels are elevated in the airways of the patients with asthma and COPD, and the opposite role of BLT1 and BLT2 in allergic inflammation implies that drug development should target BLT1 and BLT2 differently," said Hiromasa Inoue, M.D., study author from the Department of Pulmonary Medicine at the Graduate School of Medical and Dental Sciences at Kagoshima University in Kagoshima, Japan. "We hope that better anti-asthma drugs or anti-COPD drugs will be produced in the future to treat millions of patients who suffer from severe asthma and COPD."

To make this discovery, scientists compared the allergic reactions in BLT2-gene deleted mice to those in normal mice. Then an allergic asthma reaction was provoked by inhalation of allergens. BLT2-gene deleted mice showed more inflammatory cells in the lung compared to normal mice. Without the BLT2 gene, lung allergic inflammation was stronger than that of normal mice. The production of interleukin-13, an important mediator of allergic inflammation from T lymphocytes, was increased in the group without the BLT2 gene. Results suggest that targeting these two receptors differently and/or separately could achieve vastly different outcomes. Conventional anti-leukotriene B4 drugs block both of the pathways induced by BLT1 and BLT2. By manipulating the specific target, it may be possible to develop more effective anti-leukotriene B4 drugs.

"This is one case where BLT isn't a sandwich! Distinguishing between BLT1 and BLT2 is an important step forward to developing more effective drugs for lung inflammation," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "Understanding the specific roles of these and other receptors allow researchers to identify new drug targets, which in turn can lead to new and more effective drugs."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
2. BUSM researchers identify key regulator of inflammatory response
3. Invisible helpers: How probiotic bacteria protect against inflammatory bowel diseases
4. Scientists discover new inflammatory target
5. Researchers say tart cherries have the highest anti-inflammatory content of any food
6. Controlling inflammatory and immune responses
7. Scientists discover molecular link between circadian clock disturbances and inflammatory diseases
8. Promising new drug target for inflammatory lung diseases
9. Quantum dots deliver Vitamin D to tumors for possible inflammatory breast cancer treatment
10. New research examines connection between inflammatory stimulus and Parkinsons disease
11. Scientists discover switch in plants to create flowers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... (NYSE: DAL ) customers now can use fingerprints instead of ... Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May ... boarding process to allow eligible Delta SkyMiles Members who are enrolled in ...
(Date:6/23/2017)... ITHACA, N.Y. , June 23, 2017  IBM ... in dairy research, today announced a new collaboration using ... the chances that the global milk supply is impacted ... project, Cornell University has become the newest academic institution ... Chain, a food safety initiative that includes IBM Research, ...
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
Breaking Biology News(10 mins):
(Date:8/15/2017)... STANFORD, Calif. , Aug. 15, 2017 After spending ... resources and support with crowdsourced data collection, GeneFo now offers this ... interested in aligning and amplifying support, adherence, and data collection vis ... with medical foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... August 15, 2017 , ... ... Asian exhibitions for analytical and scientific instruments. This year’s symposium, organized by the ... in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will discuss novel ionization ...
(Date:8/15/2017)... NY (PRWEB) , ... August 15, 2017 , ... ... first time on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and ... held February 7-9, 2018, at The Roosevelt Hotel in New York City. , “With ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every ... Key researchers in the antibody community have recently come together to address this ... in the laboratory. , The team at Thermo Fisher Scientific ...
Breaking Biology Technology: